Biogen, Eisai report design of real-world study of Alzheimer’s treatment
Biogen Inc. and partner Eisai Co. Ltd. on July 29 revealed the design of an upcoming study of their controversial Alzheimer’s treatment, Aduhelm.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
FDA approves GSK’s Nucala for use in adults with chronic rhinosinusitis with nasal polyps
/in Adults, Approvals, Blockbusters, Chronic Rhinosinusitis, Chronic rhinosinusitis with nasal polyps (CRSwNP), FDA, Nasal PolypsThe U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5, as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
New Infusion of Cash For Trio of Global Biotech And Pharma Firms
/in Biotech, Business, China, Clinical Trials, Financing, Funding, Pharma Companies, Precision Oncology, R&D, Series B, Series D FinancingThree pharmaceutical and biotechnology companies announced the recent success of their respective funding rounds to support future efforts.
Putting patients at the heart of cell and gene therapy
/in Biotech, Cell Therapy, Gene Therapy, HCPs, Healthcare Communications Networks, Marketing & Advertising, Patient Experience, PatientsCell and gene therapies (C>s) present opportunities to not only treat disease, but to restore function and improve disease management. Although the opportunities with C>s are continuing to expand, there is a widening gap between the potential of treatment advances and the patient experience. The industry is beginning to acknowledge the problems faced in one of healthcare’s most complex areas for patient experience, according to EmerGENE’s Nareda Mills (Global President Patient Solutions) and Ben Beckley (Global Lead).
Cello Health Advantage Announces New Staff
/in Appointments, Healthcare Communications Agencies, Marketing & Advertising, New Hire, People on the MoveCello Health Advantage, a boutique consulting firm supporting new products and business development as part of Cello Health’s commercialization service offering from very early stage to launch and beyond, announced several staff additions.
Q&A With Ogilvy Health’s Global CEO Kim Johnson
/in Appointments, Business, Cannes/Lions Health, Coronavirus Disease (COVID-19) Pandemic, Health & Wellness, Healthcare, Healthcare Communications Agencies, Healthcare Communications Networks, Marketing & Advertising, New Hire, People on the Move, Pharma, Q&AMed Ad News spoke with Kim Johnson, the new Global CEO of Ogilvy Health, about how she came to the position, her first days on the job, and how she expects the worldwide agency network will expand in the future.
AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges
/in AstraZeneca, Business, Clinical Data, Covid-19 Data, COVID-19 Vaccines, Oxford University, Quarterly results, R&D, Sales, SharesSecond-quarter 2021 sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on July 29 again delayed the U.S. application for approval as the company gathers more data for submissions.
Eli Lilly and Kumquat Seek Enhanced Tumor-Specific Immune Response
/in Business, Cancer, Deals, Eli Lilly, Immune Response, Immuno-oncology, R&D, Small Molecules, TumorsLoxo Oncology, a division of Eli Lilly, and Kumquat Biosciences teamed up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specific immune responses in cancer patients.
U.S. FDA allows Lilly’s COVID-19 drug to be taken without remdesivir
/in Baricitinib, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Eli Lilly, Emergency Use Authorization (EUA), FDA, Hospitalized COVID-19 Patients, Incyte, R&D, Remdesivir, TherapeuticsThe U.S. health regulator expanded the emergency use authorization for Eli Lilly’s baricitinib for Covid-19, saying the arthritis medicine could now be used without taking Gilead’s drug remdesivir along with the product.
FDA Approves First-Ever Interchangeable Biosimilar
/in Approvals, Biologics License Application (BLA), Blockbusters, FDA, Interchangeable Biosimilars, Market exclusivity, Pharmacy-level substitution, Therapeutics, Type 1 Diabetes, Type 2 DiabetesThe U.S. Food and Drug Administration approved Viatris and Biocon Biologics’ Semglee (insulin glargine-yfgn injection) as the first interchangeable biosimilar product, which is indicated to control high blood sugar in adults with Type 2 diabetes as well as adults and pediatric patients with Type 1 diabetes.
